Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

被引：2
|
作者：
O'Cearbhaill, R. E. [1 ,2 ]
Moore, K. N. [3 ,4 ]
Yeku, O. [5 ]
Liu, J. F. [6 ]
Bouberhan, S. [5 ]
Hamilton, E. P. [7 ]
Hou, J. Y. [8 ]
Van Nieuwenhuysen, E. [9 ]
Papadimitriou, K. [10 ]
Yoo, S-Y. [11 ]
Govindraj, S. [11 ]
Brouwer-Visser, J. [11 ]
Peterman, M. [11 ]
Schmidt, T. [11 ]
Barnes, B. [11 ]
Madia, P. [11 ]
Zhu, M. [11 ]
Uldrick, T. S. [11 ]
Miller, E. A. [11 ]
O'Malley, D. [12 ,13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sarah Cannon Res Inst, Oklahoma City, OK USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN 5 USA
[8] Columbia Univ, Div Gynecol Oncol, Med Ctr, New York, NY USA
[9] Leuven Canc Inst, Dept Oncol, Leuven, Belgium
[10] Univ Antwerp Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Antwerp, Belgium
[11] Regeneron Pharmaceut Inc, Global Dev, Tarrytown, NY USA
[12] Ohio State Univ, Div Gynecol Oncol, Columbus, OH USA
[13] James Canc Ctr, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
754P
引用
收藏
页码：S516 / S517
页数：2
相关论文
共 50 条
  • [21] Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Meniawy, T.
    Richardson, G.
    Townsend, A.
    Desai, J.
    Gan, H.
    Friedlander, M.
    Horvath, L.
    Jameson, M. B.
    Sandhu, S.
    Wu, Z.
    Qin, Z.
    Kang, K.
    Markman, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] A PHASE I/II STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Lakhani, Nehal
    Johnson, Melissa
    Groisberg, Roman
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Skokos, Dimitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A565 - A565
  • [23] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
    Drake, Charles G.
    Zhang, Jingsong
    Stein, Mark N.
    Xu, Yuanfang
    Seebach, Frank A.
    Lowy, Israel
    Mohan, Kosalai Kal
    Kroog, Glenn
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
    Zhang, Jingsong
    Stein, Mark N.
    Kelly, William Kevin
    Tsao, Che-Kai
    Falchook, Gerald Steven
    Xu, Yuanfang
    Seebach, Frank A.
    Lowy, Israel
    Mohan, Kosalai Kal
    Kroog, Glenn
    Miller, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] CHEMOSENSITIVITY AFTER ANTI-PD-1 ANTIBODY NIVOLUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER
    Inayama, Y.
    Hamanishi, J.
    Matsumura, N.
    Murakami, R.
    Abiko, K.
    Yamaguchi, K.
    Baba, T.
    Horie, K.
    Konishi, I.
    Mandai, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 709 - 709
  • [26] Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
    Lee, K-W.
    Park, J.
    Oh, D-Y.
    Kim, S. H.
    Sabanathan, D.
    Kim, T. M.
    Kim, M.
    Yoon, J.
    Lee, H.
    Park, S.
    Paeng, K.
    Ock, C-Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S838 - S838
  • [27] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study
    Li, Qun
    Zhao, Wei
    Wang, Wei
    Chen, Po
    Niu, Zuoxing
    Ni, Shuqin
    Luo, Suxia
    Qiao, Junjing
    Wang, Mingxi
    Li, Yong
    He, Yan
    Liu, Tao
    Li, Tao
    Cai, Shengli
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
    An, Jusheng
    Tang, Jie
    Li, Benjamin X.
    Xiong, Huihua
    Qiu, Hui
    Luo, Lin
    Wang, Li
    Wang, Danbo
    Zhou, Qi
    Xu, Qin
    Song, Honglin
    Zhang, Yunyan
    Zhang, Hongping
    Li, Yujie
    Yu, Xiaohui
    Zhang, Jing
    Ng, Rachel
    Zhao, Wayne
    Wong, Michael
    Dai, Xiangrong
    Li, Guiling
    Wu, Lingying
    CLINICAL CANCER RESEARCH, 2022, 28 (23) : 5098 - 5106
  • [29] Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors A Phase 1 Dose-Escalation Trial
    Johnson, Melissa L.
    Braiteh, Fadi
    Grilley-Olson, Juneko E.
    Chou, Jeffrey
    Davda, Jasmine
    Forgie, Alison
    Li, Ruifeng
    Jacobs, Ira
    Kazazi, Farhad
    Hu-Lieskovan, Siwen
    JAMA ONCOLOGY, 2019, 5 (07) : 999 - 1007
  • [30] A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).
    Winer, Ira Seth
    Shields, Anthony Frank
    Yeku, Oladapo O.
    Liu, Joyce F.
    Peterman, Mary Jane
    Yoo, Suk Young
    Lowy, Israel
    Yama-Dang, N. Alice
    Goncalves, Priscila Hermont
    Kroog, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345